# A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

> **NCT00772486** · PHASE1 · COMPLETED · sponsor: **Memgen, LLC** · enrollment: 13 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** ISF35

## Key facts

- **NCT ID:** NCT00772486
- **Lead sponsor:** Memgen, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-04
- **Final completion:** 2013-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772486, "A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00772486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*